Segment information We operate in one business segment   human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product sales; revenues and long-lived assets by geographic area; and revenues from major customers are presented below. Revenues Revenues were as follows for the years ended December 31, 2013 , 2012 and 2011 (in millions): 2013 2012 2011 Product sales: Neulasta ® $ 4,392 $ 4,092 $ 3,952 NEUPOGEN ® 1,398 1,260 1,260 ENBREL 4,551 4,236 3,701 Aranesp ® 1,911 2,040 2,303 EPOGEN ® 1,953 1,941 2,040 Sensipar ® /Mimpara ® 1,089 950 808 Vectibix ® 389 359 322 Nplate ® 427 368 297 XGEVA ® 1,019 748 351 Prolia ® 744 472 203 Kyprolis ® 73     Other 246 173 58 Total product sales 18,192 16,639 15,295 Other revenues 484 626 287 Total revenues $ 18,676 $ 17,265 $ 15,582 Geographic information Outside the United States, we sell products principally in Europe and Canada. The geographic classification of product sales was based on the location of the customer. The geographic classification of all other revenues was based on the domicile of the entity from which the revenues were earned. Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions): Years ended December 31, 2013 2012 2011 Revenues: United States $ 14,480 $ 13,415 $ 11,985 Rest of the world (ROW) 4,196 3,850 3,597 Total revenues $ 18,676 $ 17,265 $ 15,582 December 31, 2013 2012 Long-lived assets: United States $ 2,772 $ 2,906 Puerto Rico 1,822 1,908 ROW 755 512 Total long-lived assets $ 5,349 $ 5,326 Major customers In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of distributing our products to healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors dep